None listed
Conditions
Brief summary
Haematopoietic stem cell transplantation, in conjunction with chemotherapy, is a standard treatment for patients with myeloma. However, stem cell transplantation can have major treatment-related complications, including increased risk of infection and inflammatory conditions, as well as a decrease in quality of life. Vitamin C is known to exhibit antioxidant and anti-inflammatory functions and is required for optimal immune system functioning. Significantly decreased plasma vitamin C concentrations have been observed in myeloma patients undergoing conditioning chemotherapy followed by stem cell transplantation. The purpose of this study is to investigate the effect of oral vitamin C supplementation of myeloma patients undergoing stem cell transplantation on plasma vitamin C status. The effect of supplementation on the incidence and severity of severe infection and oral mucositis (inflammation of membranes lining the digestive tract), and changes in patient quality of life will also be monitored in comparison with a placebo.
Interventions
Vitamin C tablets: 1g twice daily for 5 weeks
Commencing one week prior to HSCT
Adherence monitored by tablet return and plasma levels
Sponsors
University of Otago
Study design
Allocation
Randomised controlled trial
Primary purpose
Treatment
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Myeloma patient scheduled for HSCT 2. Aged 18 years and over
Exclusion criteria
1. Not able to provide informed consent 2. Poor renal function (creatinine clearance <10 mls/sec or glomerular filtration rate <15) 3. Haemochromatosis
Outcome results
None listed